Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB
The purpose of this study is to evaluate the effectiveness of Detrusitol (tolterodine tartrate) SR, 4 mg once daily, on patient's perception of the symptoms of overactive bladder and which of these bothersome symptoms are improved with treatment.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Global Phase IV, Double-Blind, Placebo-Controlled, Randomized Trial To Evaluate The Effectiveness Of Detrusitol Sr 4mg On Patient's Perception Of Bladder Condition (PPBC).|
- Patient Perception of Bladder Condition at 12 weeks of treatment compared to placebo.
- Other safety and efficacy measures at 12 weeks of treatment.
|Study Start Date:||September 2004|
|Estimated Study Completion Date:||October 2005|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00143377
|Study Director:||Pfizer CT.gov Call Center||Pfizer|